Psychosis, Schizophrenia
Conditions
Brief summary
The purpose of this study is to determine if candidate polymorphisms in brain-derived neurotrophic factor (BDNF) and catechol-o-methyl transferase (COMT) are predictive of psychosis disorder severity, symptomology, and resolution in patients at BCPP. A secondary objective will be to form a biorepository of blood and saliva samples from patients at BCPP so that further genetic, proteonomic and pharmacogenomic studies may be done to gain insight into the genetic basis of differences in psychosis disorder presentation and manifestation, and differences in response to antipsychotic drug treatment.
Detailed description
This is a population-based, genetic-association, candidate polymorphism study. It will involve a prospective and a retrospective component. A blood draw or saliva sample will be performed during the participant's admission to BCPP, which may occur at any point during the participant's length of stay. When a participant has been deemed 'Ready for Discharge' by his/her attending psychiatrist at BCPP, a full phenotype will be obtained via retrospective chart review. Genetic analyses and determination of protein levels will be performed after chart review. Following fulfillment of the primary study objective, the remaining blood and saliva samples will be stored in the biobank over the long-term.
Interventions
Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
Sponsors
Vancouver Coastal Health
University of British Columbia
Study design
Observational model
COHORT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Admission to BCPP. * Has provided written informed consent.
Exclusion criteria
* None.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Creation of biorepository of blood samples for future genetic, proteonomic and pharmacogenomic studies. | One visit during participant's stay at BCPP, an expected average of 6 months | A biobank of stored samples will be used to determine the genetic variability in psychosis disorder. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Identification of single-nucleotide polymorphisms (SNPs) in the BDNF and COMT genes | One visit during participant's stay at BCPP, an expected average of 6 months | We will determine if specific genetic variants in BDNF and COMT genes are associated with psychosis disorder severity, symptomology and resolution. |
| Medical Chart Review | One visit during participant's stay at BCPP, an expected average of 6 months | A medical chart review will be done on hard-copy medical charts at BCPP. |
Countries
Canada
Contacts
Primary ContactDelrae Fawcett, M.Sc.
Backup ContactHeidi Boyda, Ph.D.
Outcome results
None listed